Expression of 11beta-hydroxysteroid dehydrogenase 2 contributes to glucocorticoid resistance in lymphoblastic leukemia cells

Leukemia Research

Volumn 35, Issue 12, 2011, Pages 1644-1648

  Sai, Shuji ^a,b   Nakagawa, Yuichi ^a   Yamaguchi, Rie ^a   Suzuki, Masako ^a   Sakaguchi, Kimiyoshi ^a   Okada, Shuichi ^a   Seckl, Jonathan R ^b   Ohzeki, Takehiko ^a   Chapman, Karen E ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

11 Hydroxysteroid dehydrogenase 2; Acute lymphoblastic leukemia; Glucocorticoid resistance

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; CARBENOXOLONE; CASPASE 3; CASPASE 7; CORTISONE; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR ALPHA; HYDROCORTISONE; PREDNISOLONE;

ARTICLE; CANCER RESISTANCE; CELL DEATH; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; PRIORITY JOURNAL;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE, TUMOR; DEXAMETHASONE; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, LEUKEMIC; GLUCOCORTICOIDS; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISOLONE; RECEPTORS, GLUCOCORTICOID;

EID: 80055115992     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.07.002     Document Type: Article

References (33)

1. Kofler R. The molecular basis of glucocorticoid-induced apoptosis of lymphoblastic leukemia cells. Histochem Cell Biol 2000, 114:1-7.
2. Tissing W.J., Meijerink J.P., den Boer M.L., Pieters R. Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia 2003, 17:17-25.
3. Kofler R., Schmidt S., Kofler A., Ausserlechner M.J. Resistance to glucocorticoid-induced apoptosis in lymphoblastic leukemia. J Endocrinol 2003, 178:19-27.
4. Ploner C., Schmidt S., Presul E., et al. Glucocorticoid-induced apoptosis and glucocorticoid resistance in acute lymphoblastic leukemia. J Steroid Biochem Mol Biol 2005, 93:153-160.
5. Schrappe M., Arico M., Harbott J., et al. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998, 92:2730-2741.
6. Dördelmann M., Reiter A., Borkhardt A., et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999, 94:1209-1217.
7. Schrappe M., Reiter A., Zimmermann M., et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000, 14:2205-2222.
8. Schwartz C.L., Thompson E.B., Gelber R.D., et al. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol 2001, 19:1040-1046.
9. Gruber G., Carlet M., Türtscher E., et al. Levels of glucocorticoid receptor and its ligand determine sensitivity and kinetics of glucocorticoid-induced leukemia apoptosis. Leukemia 2009, 23:820-823.
10. Pui C.H., Costlow M.E. Sequential studies of lymphoblast glucocorticoid receptor levels at diagnosis and relapse in childhood leukemia: an update. Leuk Res 1986, 10:227-229.
11. Tissing W.J., Lauten M., Meijerink J.P., et al. Expression of the glucocorticoid receptor and its isoforms in relation to glucocorticoid resistance in childhood acute lymphocytic leukemia. Haematologica 2005, 90:1279-1281.
12. Seckl J.R., Chapman K.E. The 11β-hydroxysteroid dehydrogenase system, a determinant of glucocorticoid and mineralocorticoid action. Eur J Biochem 1997, 249:361-364.
13. Chapman K.E., Coutinho A.E., Gray M., Gilmour J.S., Savill J.S., Seckl J.R. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in the inflammatory response. Mol Cell Endocrinol 2009, 301:123-131.
14. Diederich S., Eigendorff E., Burkhardt P., et al. 11β-Hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab 2002, 87:5695-5701.
15. Coulter C.L., Smith R.E., Stowasser M., Sasano H., Krozowski Z.S., Gordon R.D. Expression of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD-2) in the developing human adrenal gland and human adrenal cortical carcinoma and adenoma. Mol Cell Endocrinol 1999, 154:71-77.
16. Koyama K., Myles K., Smith R., Krozowski Z. Expression of the 11β-hydroxysteroid dehydrogenase type II enzyme in breast tumors and modulation of activity and cell growth in PMC42 cells. J Steroid Biochem Mol Biol 2001, 76:153-159.
17. Rabbitt E.H., Gittoes N.J., Stewart P.M., Hewison M. 11β-Hydroxysteroid dehydrogenases, cell proliferation and malignancy. J Steroid Biochem Mol Biol 2003, 85:415-421.
18. Hongo T., Yajima S., Sakurai M., Horikoshi Y., Hanada R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 1997, 89:2959-2965.
19. Sai S., Nakagawa Y., Sakaguchi K., et al. Differential regulation of 11β-hydroxysteroid dehydrogenase-1 by dexamethasone in glucocorticoid-sensitive and -resistant childhood lymphoblastic leukemia. Leuk Res 2009, 33:1696-1698.
20. Brown R.W., Chapman K.E., Kotelevtsev Y., et al. Cloning and production of antisera to human placental 11β-hydroxysteroid dehydrogenase type 2. Biochem J 1996, 313:1007-1017.
21. Fujisawa Y., Nakagawa Y., Li R.S., Liu Y.J., Ohzeki T. Diabetic pregnancy in rats leads to impaired glucose metabolism in offspring involving tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 expression. Life Sci 2007, 81:724-731.
22. Riml S., Schmidt S., Ausserlechner M.J., Geley S., Kofler R. Glucocorticoid receptor heterozygosity combined with lack of receptor auto-induction causes glucocorticoid resistance in Jurkat acute lymphoblastic leukemia cells. Cell Death Differ 2004, 11(Suppl. 1):S65-S72.
23. Dyson J.E., Quirke P., Bird C.C., McLaughlin J.B., Surrey C.R. Relationship between cell ploidy and glucocorticoid induced death in human lymphoid cell lines. Br J Cancer 1984, 49:731-738.
24. Ito C., Evans W.E., McNinch L., et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol 1996, 14:2370-2376.
25. Thompson E.B., Smith J.R., Bourgeois S., Harmon J.M. Glucocorticoid receptors in human leukemias and related diseases. Klin Wochenschr 1985, 63:689-698.
26. Rabbitt E.H., Lavery G.G., Walker E.A., Cooper M.S., Stewart P.M., Hewison M. Prereceptor regulation of glucocorticoid action by 11β-hydroxysteroid dehydrogenase: a novel determinant of cell proliferation. FASEB J 2002, 16:36-44.
27. Brown R.W., Diaz R., Robson A.C., et al. The ontogeny of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development. Endocrinology 1996, 137:794-797.
28. Speirs H.J., Seckl J.R., Brown R.W. Ontogeny of glucocorticoid receptor and 11β-hydroxysteroid dehydrogenase type-1 gene expression identifies potential critical periods of glucocorticoid susceptibility during development. J Endocrinol 2004, 181:105-116.
29. Brewer J.A., Sleckman B.P., Swat W., Muglia L.J. Green fluorescent protein-glucocorticoid receptor knockin mice reveal dynamic receptor modulation during thymocyte development. J Immunol 2002, 169:1309-1318.
30. Purton J.F., Monk J.A., Liddicoat D.R., et al. Expression of the glucocorticoid receptor from the 1A promoter correlates with T lymphocyte sensitivity to glucocorticoid-induced cell death. J Immunol 2004, 173:3816-3824.
31. Bostrom B.C., Sensel M.R., Sather H.N., et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003, 101:3809-3817.
32. Mitchell C.D., Richards S.M., Kinsey S.E., et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005, 129:734-745.
33. Schrappe M., Zimmermann M., Moricke A., et al. Dexamethasone in induction can eliminate one third of all relapses in childhood acute lymphoblastic leukemia (ALL): results of an international randomized trial in 3655 patients (Trial AIEOP-BFM ALL 2000) [abstract]. Blood 2008, 112:7.